Adalimumab-aacf - Biologic Drug Details

Summary for adalimumab-aacf

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for adalimumab-aacf Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for adalimumab-aacf Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for adalimumab-aacf Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Adalimumab-aacf

Last updated: February 25, 2026

What is Adalimumab-aacf?

Adalimumab-aacf is a biosimilar of the original biologic drug adalimumab (Humira). It is approved in the United States by the FDA for indications including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and plaque psoriasis. Biosimilars like adalimumab-aacf aim to provide more cost-effective alternatives once patents for reference biologics expire.

Patent and Regulatory Timeline

• Original biologic (Humira): Patents expired in the U.S. in January 2023.
• Biosimilar approval: Adalimumab-aacf received FDA approval in December 2022.
• Market entry: Commercial launch in the U.S. occurred in the first quarter of 2023.
• European Union: Biosimilar approved in 2021, market penetration began in 2022.

Market Size and Growth Drivers

Indicator	Data / Comparison
Global anti-TNF biologics market in 2022	$27 billion (Grand View Research)
Estimated biosimilar share by 2025	35-50% of anti-TNF market
U.S. biologics market in 2023	$120 billion (IQVIA)

Key growth drivers include patent expiry of Humira, rising biologic treatment rates, and patient access initiatives.

Pricing and Market Share Impact

• Humira: Maintains a list price of approximately $6,000 per month.
• Biosimilar pricing: Offers discounts of 15-30% compared to Humira.
• Market share: Biosimilars are capturing an increasing portion, projected to reach 45% of the adalimumab segment by 2025 (Evaluate Pharma, 2022).

Financial Trajectory and Revenue Projections

Year	Estimated Biosimilar Sales (USD billions)	Market Penetration	Notes
2023	$1.2 billion	10-15%	Initial uptake post-launch
2024	$3.6 billion	25-30%	Growing physician acceptance
2025	$6.0 billion	45%	Market stabilization and further expansion

These estimates assume a price discount averaging 25%, favorable payer policies, and increasing clinician adoption.

Competitive Landscape

Competitors	Market Presence	Key Differentiators
Filsari (Amgen)	Approved in US, 2023	Slightly lower price point, broad distribution
Imraldi (Sandoz)	Approved in EU, 2021	Established manufacturing network
Hadlima (Samsung)	Approved in US, 2023	Competitive pricing, manufacturing scale

Market dominance will depend on manufacturer capacity, payer coverage, and patient access strategies.

Key Policy and Market Access Factors

• Payer policies: Increasing acceptance of biosimilars to reduce healthcare costs.
• Regulatory environment: Accelerated approvals and interchangeability designations influence uptake.
• Patient and provider acceptance: Education campaigns improve prescriber and patient confidence.

Risks and Challenges

• Reimbursement hurdles: Delays or restrictions in formulary placement.
• Market saturation: Competition within biosimilars for the same reference product.
• Legal disputes: Patent litigation could delay or limit market entry of biosimilars.

Summary

Adalimumab-aacf is positioned to capture substantial market share shortly after launch, driven by patent expiries of reference biologics and favorable regulatory and payer trends. Revenue projection models anticipate a sustained growth trajectory, with biosimilars expected to account for approximately 45% of the adalimumab market by 2025, contributing significantly to the overall anti-TNF biologics market expansion.

Key Takeaways

• Biosimilar adalimumab-aacf entered the U.S. market in early 2023, targeting the large adalimumab market.
• Market share growth depends on pricing strategies, payer acceptance, and physician adoption.
• Revenue from biosimilars projected to reach $6 billion globally by 2025.
• Competitive positioning relies on manufacturing scale, pricing, and regulatory designations.
• The U.S. biosimilar landscape continues to evolve with policy shifts favoring biosimilar uptake.

FAQs

1. How does adalimumab-aacf differ from the original Humira?
   It is a biosimilar with demonstrated high similarity in efficacy, safety, and immunogenicity, but contains no clinically meaningful differences.

2. What is the expected timeline for biosimilar market penetration?
   Initial market share was approximately 10-15% in 2023; projections suggest growth to over 45% by 2025.

3. What factors influence biosimilar pricing strategies?
   Regulatory policies, manufacturing costs, competitive dynamics, and payer negotiations determine pricing.

4. Are biosimilar adalimumabs interchangeable with Humira?
   Interchangeability status depends on FDA designation; as of now, adalimumab-aacf is not designated as interchangeable.

5. What risks could slow the market growth of adalimumab-aacf?
   Legal patent disputes, limited physician familiarity, and payer restrictions could hinder growth.

---

References

[1] Grand View Research. (2022). Anti-TNF Biologics Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2023). The Future of Biologics: Market Overview.
[3] Evaluate Pharma. (2022). Biosimilar Market Forecasts, 2022-2025.